These compounds influence key metabolic and signaling pathways, including PI3K/Akt/mTOR, NF-κB, and Wnt/β-catenin, suggesting their potential as adjuncts to conventional chemotherapy and their role in improving treatment outcomes in ovarian cancer management. Here, AKT1 is linked to ovarian carcinoma.